SpliceBio CEO: The Route From US Academic To Spanish Gene Tech Entrepreneur

Startup Co-founder And CEO Explains The Difficult Process Of ‘Rolling Down The Sleeves’ And Allowing Strategic Activity To Take Precedence

From an early stage in his career, Miquel Vila-Perelló saw himself as a research academic. It was an ambition he duly fulfilled. Later, seeing the greater potential to bring benefit to human health by forming his own company, he co-founded SpliceBio, a Spain-based startup focusing on gene therapies for rare diseases.

Older eye
Stargardt’s disease, a genetic eye disorder that causes retinal degeneration and vision loss, is the most prevalent of the rare diseases of the retina

Rising Leaders Home

Making considered changes that will deliver benefits in the longer-term, regardless of any short- term disruption or pain, calls for...

More from Business Strategy

More from In Vivo

Deals In Depth: June 2025

 
• By 

Five $1bn+ alliances were penned in June, and four exceeded $2bn.

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By 

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

Podcast: Oxolife’s Agnés Arbat, Winner Of The European Prize For Women Innovators

 
• By 

Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.